- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Poll
Article
POLL: Have Your Patients Asked About Cabtreo for Acne?
Author(s):
Key Takeaways
- Cabtreo is the first FDA-approved fixed-dose triple-combination gel for acne vulgaris, combining clindamycin, adapalene, and benzoyl peroxide.
- Phase 2 trials showed 52.5% of patients achieved significant improvement in acne severity with Cabtreo treatment.
Click here to answer this week's acne poll.
Have your patients asked about Cabtreo for acne?
Cabtreo (Ortho Dermatologics; formerly known as IDP-126) was approved by the US Food and Drug Administration (FDA) in October 2023 for the treatment of patients aged 12 years and older with acne vulgaris. Cabtreo is the first FDA-approved fixed-dose triple-combination gel (clindamycin 1.2%/adapalene 0.15%/benzoyl peroxide 3.1%) for patients with acne. Cabtreo is expected to be available in Q1 of 2024.
In the phase 2 trial of Cabtreo, more than half (52.5%) of patients treated with Cabtreo achieved treatment success as measured by a 2-point or greater reduction from baseline in Evaluator’s Global Severity Score and clear or almost clear skin. In the first of the phase 3 trials, the proportion of patients treated with Cabtreo achieving clear or almost clear skin (49.6%) was significantly greater than patients being treated with a vehicle gel (24.9%). The second phase 3 trial demonstrated consistent significant rates of treatment success among Cabtreo- treated patients (50.5%) versus patients in the vehicle gel group (20.5%).
What are your thoughts about Cabtreo as the newest acne topical? Email us at DTEditor@mmhgroup.com.
